Ayrmid appoints Ideogen as exclusive partner for Omisirge in EMEA
Ayrmid appointed Ideogen as its exclusive partner to launch a managed access program for Omisirge across 55 markets spanning Europe, MENA and CIS, covering both FDA-approved Omisirge indications.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.